Tissue allografts cannot be reliably traced from donor to recipient, so when a contaminated batch is discovered, some patients are never found

Between 1994 and 2007, the FDA recalled 61,607 tissue allografts — the vast majority (96.5%) musculoskeletal grafts like bone, tendon, and cartilage used in orthopedic and dental surgeries. When a tissue recall is issued — because the donor later tested positive for an infection, or contamination was discovered during processing — every patient who received tissue from that donor needs to be identified, notified, and tested. But in practice, the traceability chain routinely breaks. Federal FDA regulations require tissue banks to track products to the "consignee" (the hospital or surgical center that received the tissue) but only "encourage" tracking all the way to the individual patient. Hospitals are asked to return implant records to tissue banks after surgery, but compliance is voluntary and cannot be enforced unless the hospital is accredited by the Joint Commission. The consequence is that during recall investigations, some recipients are simply never found. A tissue bank knows it shipped a bone allograft to Hospital X, but Hospital X may not have recorded which specific patient received that specific lot number, especially if the graft was used in an outpatient surgical center with less rigorous documentation. The patient may have had a knee reconstruction, received a contaminated tendon allograft, and developed a low-grade infection months later that was attributed to normal surgical complications rather than linked back to a tissue recall. Bacterial, fungal, and viral infections — including Clostridium and Creutzfeldt-Jakob disease — have been transmitted via tissue allografts from infected donors or post-mortem contamination. This gap persists because tissue banking sits in a regulatory no-man's-land between the FDA (which regulates tissue banks) and CMS/Joint Commission (which regulate hospitals). The FDA does not have jurisdiction over end-user hospitals, so it cannot mandate that hospitals track and report tissue implantation data back to tissue banks. Unlike pharmaceutical products, which have National Drug Codes and pharmacy dispensing records, tissue allografts lack a universally adopted unique device identification system that follows the product from processing through implantation. The introduction of ISBT 128 coding standards has improved identification, but implementation remains inconsistent, and many smaller tissue banks and surgical centers still use proprietary tracking systems that do not interoperate.